Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), retaining the price target of $18.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ed Arce has given his Buy rating due to a combination of factors surrounding Enanta Pharmaceuticals’ ongoing developments and future prospects. The upcoming top-line data from the Phase 2b RSVHR study expected in the third quarter of 2025 is a significant factor. This study focuses on high-risk adults, and positive results could pave the way for a Phase 3 trial, positioning the drug, zelicapavir, for registration trials in both adult and pediatric populations.
Additionally, Enanta’s engagement with regulators to determine the registration pathway for pediatric use, based on previous Phase 2 study data, is another promising aspect. The company’s strategic plans to explore partnership opportunities for its RSV programs, including another asset, EDP-323, further bolster its growth potential. The anticipated milestones in 2025, such as the RSVHR study results and regulatory discussions, are key drivers behind the Buy rating.
Arce covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Acurx Pharmaceuticals, and Akero Therapeutics. According to TipRanks, Arce has an average return of 18.6% and a 48.50% success rate on recommended stocks.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $21.00 price target.